Hras - HRas proto-oncogene, GTPase Gene

Also Known as HRAS1; c-H-ras

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 293621

About Hras

Primary_assembly 1: 196,296,263-196,300,615 reverse strand.mRatBN7.2:CM026974.1

This gene has 2 transcripts (splice variants), 224 orthologues, 41 paralogues and is associated with 104 phenotypes. Biased expression in Muscle (RPKM 343.7), Brain (RPKM 196.6) and 9 other tissues.

Summary

Predicted to enable GTPase activity; guanyl ribonucleotide binding activity; and protein C-terminus binding activity. Involved in several processes, including cellular senescence; positive regulation of DNA replication; and positive regulation of ERK1 and ERK2 cascade. Acts upstream of or within positive regulation of Ras protein signal transduction. Located in intracellular membrane-bounded organelle and plasma membrane. Used to study diabetic retinopathy and liver carcinoma. Human ortholog(s) of this gene implicated in several diseases, including Costello syndrome; autistic disorder; carcinoma (multiple); epidermal nevus; and large congenital melanocytic nevus. Orthologous to human HRAS (HRas proto-oncogene, GTPase). [provided by Alliance of Genome Resources, Apr 2022]

Hras Products (2)

mRNA Protein Name
NM_001130441.1 NP_001123913.1 GTPase HRas
NM_001098241.1 NP_001091711.1 GTPase HRas

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables protein binding IPI
IPI: Inferred from physical interaction
18514235 RGD
enables protein-containing complex binding IPI
IPI: Inferred from physical interaction
15917294 RGD
Biological Process GO Annotation Evidence References Source
involved in Ras protein signal transduction IMP
IMP: Inferred from mutant phenotype
12077341 RGD
involved in cellular senescence IEP
IEP: Inferred from expression pattern
17706954 RGD
involved in liver development IEP
IEP: Inferred from expression pattern
2581126 RGD
involved in positive regulation of DNA replication IMP
IMP: Inferred from mutant phenotype
9487126 RGD
involved in positive regulation of ERK1 and ERK2 cascade IMP
IMP: Inferred from mutant phenotype
18163378 RGD
acts upstream of or within positive regulation of Ras protein signal transduction IMP
IMP: Inferred from mutant phenotype
19029245 RGD
involved in response to isolation stress IEP
IEP: Inferred from expression pattern
19616040 RGD
Cellular Component GO Annotation Evidence References Source
located in plasma membrane IDA
IDA: Inferred from direct assay
19878719 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Hras Protein Structure

H_N_K_Ras_like

H_N_K_Ras_like: cd04138 (103 - 264)

  • 0
  • 100
  • 200
  • 290 a.a.
Protein Preferred Names Protein Names

GTPase HRas

  • H-Ras-1

  • Harvey ras1 protein

  • Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog

  • Harvey rat sarcoma virus oncogene

  • p21ras

  • transforming protein p21

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B0660 Eicosapentaenoic Acid Activator 98.09% Yes
HY-15136 Lonafarnib 99.85% Yes
HY-B0984 Fendiline hydrochloride 99.78% Unkown
HY-B0984A Fendiline 99.41% Unkown
HY-B0984R Fendiline hydrochloride (Standard) 99.76% Unkown
HY-W011269 Eicosapentaenoic Acid sodium Activator 95.78% Yes

Clinical Phase

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-176785S MCB-294 98.04% Phase 4
HY-148439 Daraxonrasib Inhibitor 99.96% Phase 3
HY-173632 AMG410 Inhibitor 99.75% Phase 1
HY-16111 BMS-214662 Inhibitor 99.86% Phase 1
HY-16373 CP-609754 Inhibitor 99.49% Phase 1

Pre-clinical Phase

Bioactive Molecules (46)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-156498 RMC-7977 Inhibitor 99.48% Unkown
HY-100002 ML162 99.52% Unkown
HY-122862 RAS inhibitor Abd-7 Inhibitor 99.57% Unkown
HY-176786 MCB-36 98.43% Unkown
HY-113849 MLS-573151 Inhibitor 99.66% Unkown
HY-123242 FTI-2153 Inhibitor 99.77% Unkown
HY-125904 4-Hydroxyretinoic acid ≥95.0% Unkown
HY-15879 LB42708 ≥99.0% Unkown
HY-175870 Eras-4001 Inhibitor 98.27% Unkown
HY-181420A BBO-11818 99.77% Unkown
HY-15873A FTI 276 TFA Inhibitor 98.31% Unkown
HY-145962A MRTX-EX185 formic Inhibitor 97.15% Unkown
HY-N10336 Notoginsenoside R4 99.90% Unkown
HY-168847 INCB159020 Inhibitor / Unkown
HY-115489A GGTI-286 TFA Inhibitor / Unkown
HY-16111A BMS-214662 hydrochloride Inhibitor 98.54% Unkown
HY-115489 GGTI-286 Inhibitor / Unkown
HY-145962 MRTX-EX185 Inhibitor / Unkown
HY-117935 GGTI-286 hydrochloride Inhibitor / Unkown
HY-123242A FTI-2153 TFA Inhibitor 98.41% Unkown
HY-RS06355 Hras Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-106603 Sulofenur / Unkown
HY-116428 L-744832 / Unkown
HY-117807 A-176120 Inhibitor / Unkown
HY-120763 LB42908 Inhibitor / Unkown
HY-122685 UC-773587 Inhibitor / Unkown
HY-128762 ML256 Inhibitor / Unkown
HY-134505 Avicin G Inhibitor / Unkown
HY-151263 G4/HDAC-IN-1 / Unkown
HY-15136B (Rac)-Lonafarnib / Unkown
HY-173632A AMG410 diTFA Inhibitor / Unkown
HY-175870A (7R)-Eras-4001 Inhibitor / Unkown
HY-176349S HRAS, Arg-13C6,15N4, Lys-13C6,15N2 / Unkown
HY-181420 (S,R,S)-BBO-11818 / Unkown
HY-182411 KRAS-IN-56 Inhibitor / Unkown
HY-183931 NPA101.3 Inhibitor / Unkown
HY-B0660S1 Eicosapentaenoic acid 1,2,3,4,5-13C5 Activator / Unkown
HY-B0660S2 Eicosapentaenoic acid-d10 / Unkown
HY-RS06354 HRAS Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS06356 Hras Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W1126467 RAS-IN-5 Inhibitor / Unkown
HY-114894 2C07 Inhibitor / Unkown
HY-120271 GGTI-297 Inhibitor / Unkown
HY-B0660A Eicosapentaenoic acid metformin Activator / Unkown
HY-N10379 19-epi-Scholaricine 99.14% Unkown
HY-N20754 DHA-free EPA oil / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Hras NCBI NCBI:3265